Translation of "hr development program" to Slovak language:
Examples (External sources, not reviewed)
| HR HR | IS HR |
| Clinical efficacy Mitotane has not been studied in a comprehensive clinical development program. | Klinická účinnosť Mitotan nebol študovaný v žiadnom rozsiahlom klinickom výskumnom programe. |
| IV 2 hr 2 IV 2 hr | 2 h 200 mg m2 i. v. |
| Cmax (µg ml) tmax (hr) T1 2 (hr) AUC (0 8) µg hr ml) | Cmax (µg ml) tmax (h) T1 2 (h) AUC( 0 8) (µg h ml) |
| HR | HR |
| Hr. | Hr. |
| The clinical development program was composed by 5 studies provided in the following table | Predložený program klinickej skúšky pozostával z dvoch štúdií v 1. fáze, MRZ BTC 9901 a MRZ BTC 0113, pričom druhá štúdia sa uskutočnila po dokončení štúdií v 3. fáze, jednej štúdie v 2. fáze (MRZ BTC 9801), |
| 95 CI for HR Non inferiority p value (HR) | 95 CI pre medián HR |
| t½ (hr) | t½ (hr) |
| Tmax (hr) | Tmax (hod) |
| hr after | ore după |
| hr after | 0, 70 |
| Tmax (hr) | Tmax (h) |
| hr 2 | 2 h |
| 180 hr). | 180 hod.). |
| In addition to promoting mobility , including managerial rotation , the HR strategy focuses on the development of ECB management . | Táto stratégia HR sa okrem podpory mobility , vrátane rotácie na manažérskych pozíciách , sústredí na rozvoj riadenia ECB . |
| Program | Program |
| Program | Program |
| program | Tag Type |
| Program | Program |
| HR (95 CI) | Medián HR (95 CI) |
| HR (95 CI) | HR (95 CI) |
| Hazard Ratio (HR) | Pomer rizika (HR) |
| T max (hr) | T max (hod) |
| N 314) HR | N 314) |
| During the clinical development program, 3,315 women (vaccine 1,657 vs. placebo 1,658) reported at least one pregnancy. | Počas klinického vývojového programu hlásilo 3 315 žien (očkovacia látka 1 657 oproti placebu 1 658) najmenej jednu graviditu. |
| The clinical development program has included over 1,900 patients, with different types of epilepsy, exposed to rufinamide. | Klinický vývojový program zahŕňal viac ako 1 900 pacientov s rôznymi typmi epilepsie, ktorí dostávali rufinamid. |
| Olanzapine plasma clearance after oral olanzapine is lower in females (18.9 l hr) versus males (27.3 l hr), and in non smokers (18.6 l hr) versus smokers (27.7 l hr). | Hodnota plazmatického klírensu olanzapínu po perorálnom olanzapíne je nižšia u žien (18, 9 l hod) ako u mužov (27, 3 l hod) a u nefajčiarov (18, 6 l hod) ako u fajčiarov (27, 7 l hod). |
| SV Main Program V 3.00 Recognition Program v 3.00 | SV Main Program V 3.00 Recognition Program v 3.00 |
| SV Main Program V 2.03 Recognition Program v 1.00 | SV Main Program V 2.03 Recognition Program v 1.00 |
| After an intravenous dose the plasma clearance of duloxetine ranges from 22 l hr to 46 l hr (mean of 36 l hr). | Plazmatický klírens po intravenóznej aplikácii dávky sa pohybuje v rozpätí 22 l h až 46 l h (priemerne 36 l h). |
| The Phase III clinical development program for Kuvan included 2, randomised placebo controlled studies in patients with PKU. | Fáza III klinického rozvojového programu pre Kuvan zahŕňala 2 randomizované, placebom kontrolované štúdie u pacientov s FKU. |
| HR Policies Staff Relations | Infraštruktúra a operácie |
| Median OS (months) HR | Medián OS (mesiace) HR |
| Clearance (ml hr kg) | Klírens (ml hod kg) |
Related searches: Management Development Program - Skills Development Program - Supplier Development Program - Workforce Development Program - Drug Development Program - Hr Development Program - Human Development Program - Teacher Development Program - Leader Development Program - Integrated Development Program -